[go: up one dir, main page]

MA29171B1 - Formulation a compression directe et procede associe - Google Patents

Formulation a compression directe et procede associe

Info

Publication number
MA29171B1
MA29171B1 MA30104A MA30104A MA29171B1 MA 29171 B1 MA29171 B1 MA 29171B1 MA 30104 A MA30104 A MA 30104A MA 30104 A MA30104 A MA 30104A MA 29171 B1 MA29171 B1 MA 29171B1
Authority
MA
Morocco
Prior art keywords
tablets
direct compression
formulations
new
vildaglipin
Prior art date
Application number
MA30104A
Other languages
English (en)
Inventor
Sabine Pfeffer
Frank Schaefer
Ricardo Schneeberger
Paul Allen Sutton
Martin Friedrich Trueby
Wolfgang Wirth
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36581880&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29171(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA29171B1 publication Critical patent/MA29171B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

CETTE INVENTION CONCERNE DES COMPRIMÉS, EN PARTICULIER DES COMPRIMÉS RÉALISÉS PAR COMPRESSION DIRECTE D'UN COMPOSÉ INHIBITEUR DE LA DIPEPTIDYLPEPTIDASE IV (DPP-IV), UN PROCÉDÉ DE PRÉPARATION AFFÉRENT, DE NOUVELLES FORMULATIONS PHARMACEUTIQUES ET DE NOUVELLES POUDRES DE FABRICATION DE COMPRIMÉS RENFERMANT DES FORMULATIONS À BASE D'INHIBITEUR DE DPP-IV CAPABLES D'ÊTRE DIRECTEMENT PRÉPARÉES SOUS FORME DE COMPRIMÉS. L'INVENTION CONCERNE ÉGALEMENT UN PROCÉDÉ DE PRÉPARATION DES COMPRIMÉS QUI CONSISTE À MÉLANGER L'INGRÉDIENT ACTIF AVEC DES EXCIPIENTS SPÉCIFIQUES DANS LES NOUVELLES FORMULATIONS PUIS À PRÉPARER DIRECTEMENT LES FORMULATIONS DANS LES COMPRIMÉS À COMPRESSION DIRECTE. L'INVENTION CONCERNE ÉGALEMENT UNE DISTRIBUTION GRANULOMÉTRIQUE DE VILDAGLIPTINE ET UNE NOUVELLE FORME CRISTALLINE DE VILDAGLIPTINE CONVENANT PARTICULIÈREMENT À LA PRÉPARATION DE COMPRIMÉS AMÉLIORÉS AINSI QUE D'AUTRES COMPOSITIONS PHARMACEUTIQUES.
MA30104A 2005-01-18 2007-07-26 Formulation a compression directe et procede associe MA29171B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64464505P 2005-01-18 2005-01-18
US69048405P 2005-06-14 2005-06-14

Publications (1)

Publication Number Publication Date
MA29171B1 true MA29171B1 (fr) 2008-01-02

Family

ID=36581880

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30104A MA29171B1 (fr) 2005-01-18 2007-07-26 Formulation a compression directe et procede associe

Country Status (19)

Country Link
US (3) US20080299190A1 (fr)
EP (1) EP1841413A2 (fr)
JP (1) JP2008527004A (fr)
KR (1) KR20070100291A (fr)
AR (1) AR052878A1 (fr)
AU (2) AU2006206670B2 (fr)
BR (1) BRPI0606731A2 (fr)
CA (1) CA2593359A1 (fr)
GT (1) GT200600008A (fr)
IL (1) IL183762A0 (fr)
MA (1) MA29171B1 (fr)
MX (1) MX2007008679A (fr)
NO (1) NO20074048L (fr)
NZ (1) NZ555576A (fr)
PE (1) PE20061017A1 (fr)
RU (1) RU2007131503A (fr)
TN (1) TNSN07274A1 (fr)
TW (1) TW200637616A (fr)
WO (1) WO2006078593A2 (fr)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
RS52163B (sr) 2004-02-05 2012-08-31 Kyorin Pharmaceutical Co. Ltd. Derivati bicikloestra
JP5025468B2 (ja) * 2004-06-17 2012-09-12 メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン メマンチン又はネラメキサンの直接圧縮によって製造された、飲用に適した即効型錠剤
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
JOP20180109A1 (ar) * 2005-09-29 2019-01-30 Novartis Ag تركيبة جديدة
AU2006306420A1 (en) * 2005-10-25 2007-05-03 Merck Sharp & Dohme Corp. Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension
EP1962827A4 (fr) 2005-12-16 2011-02-16 Merck Sharp & Dohme Compositions pharmaceutiques contenant des combinaisons d'inhibiteurs de la dipeptidylpeptidase 4 avec de la métformine
WO2007102286A1 (fr) 2006-03-08 2007-09-13 Kyorin Pharmaceutical Co., Ltd. Procede de production d'un derive aminoacetylpyrrolidinecarbonitrile et intermediaire utilise pour sa production
EP1852108A1 (fr) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Compositions d'inhibiteurs de la DPP IV
KR101452915B1 (ko) 2006-05-04 2014-10-21 베링거 인겔하임 인터내셔날 게엠베하 다형태
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
JP2010518004A (ja) * 2007-02-01 2010-05-27 ネフロジェン， エルエルシー 幹細胞ホーミングの増強および臓器機能障害または臓器不全の治療
US8143427B2 (en) 2007-03-22 2012-03-27 Kyorin Pharmaceutical Co., Ltd. Method for producing aminoacetylpyrrolidinecarbonitrile derivative
CL2008002427A1 (es) * 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
DE102007040952A1 (de) * 2007-08-30 2009-03-05 Miele & Cie. Kg Upright-Staubsauger
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PL2275108T3 (pl) * 2008-05-14 2015-01-30 Sanwa Kagaku Kenkyusho Co Preparat farmaceutyczny zawierający inhibitor dpp-iv i inny terapeutyczny środek na cukrzycę w postaci stosowanej równocześnie lub w postaci połączonej
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
JP5476305B2 (ja) 2008-08-07 2014-04-23 杏林製薬株式会社 ビシクロ［２．２．２］オクチルアミン誘導体の製造方法
EP2327406A4 (fr) * 2008-08-14 2014-04-09 Kyorin Seiyaku Kk Composition pharmaceutique stabilisée
WO2010018217A2 (fr) 2008-08-15 2010-02-18 Boehringer Ingelheim International Gmbh Composés organiques pour la cicatrisation de lésion
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AR075204A1 (es) 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
PT2395983T (pt) 2009-02-13 2020-07-03 Boehringer Ingelheim Int Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dp-iv e opcionalmente um agente antidiabético adicional e suas utilizações
CN102316875A (zh) 2009-02-13 2012-01-11 贝林格尔.英格海姆国际有限公司 用于治疗i型糖尿病、ii型糖尿病、葡萄糖耐量降低或高血糖症的sglt-2抑制剂
DK2395968T3 (da) * 2009-02-13 2024-03-04 Boehringer Ingelheim Int Farmaceutisk sammensætning omfattende glucopyranosyldiphenylmethanderivater, farmaceutisk doseringsform deraf, fremgangsmåde til deres forberedelse og anvendelser deraf til forbedret glykæmisk kontrol hos en patient
UY32427A (es) * 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
AU2010212823B2 (en) 2009-02-13 2016-01-28 Boehringer Ingelheim International Gmbh Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
WO2010110436A1 (fr) 2009-03-27 2010-09-30 杏林製薬株式会社 Préparation à libération prolongée de type matrice contenant un additif basique
EA020798B1 (ru) * 2009-09-30 2015-01-30 Бёрингер Ингельхайм Интернациональ Гмбх СПОСОБ ПОЛУЧЕНИЯ КРИСТАЛЛИЧЕСКОЙ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ]БЕНЗОЛА
ES2546762T3 (es) 2009-09-30 2015-09-28 Boehringer Ingelheim International Gmbh Procedimientos para preparar derivados de bencil-benceno sustituidos con glucopiranosilo
UY32919A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
KR20120107080A (ko) 2009-11-27 2012-09-28 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
WO2011113947A1 (fr) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combinaisons d'agonistes de gpr119 et d'inhibiteurs de dpp-iv, linagliptine, pour le traitement du diabète et d'états apparentés
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
KR20220025926A (ko) 2010-06-24 2022-03-03 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
WO2012060847A1 (fr) * 2010-11-07 2012-05-10 Targegen, Inc. Compositions et procédés de traitement de la myélofibrose
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
TR201107482A1 (tr) 2010-12-21 2012-07-23 Sanovel İlaç San.Ve Ti̇c.A.Ş. Vildagliptin ve gliklazidin iki tabakalı kombinasyon kompozisyonu.
EP2468268B1 (fr) 2010-12-21 2017-12-13 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Composition de combinaison de vildagliptine et de gliclazide
TR201101809A1 (tr) 2010-12-21 2012-07-23 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Vildagliptin ve glimepirid kombinasyonları.
TR201010683A1 (tr) 2010-12-21 2012-07-23 Sanovel İlaç San. Ve Ti̇c. A.Ş. Vildagliptin formülasyonları.
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
EP2753328A1 (fr) 2011-09-07 2014-07-16 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Formulations d'inhibiteur de dpp-iv
EP2572704A1 (fr) 2011-09-22 2013-03-27 Sanovel Ilac Sanayi ve Ticaret A.S. Formulations orodispersibles de la vildagliptine
EP2578208B1 (fr) 2011-10-06 2014-05-21 Sanovel Ilac Sanayi ve Ticaret A.S. Formulations posologiques solides d'inhibiteurs DPP-IV
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
IN2012MU01383A (fr) 2012-05-04 2014-02-28
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013171166A1 (fr) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de dpp-4 pour l'utilisation dans le traitement de sirs et/ou d'une sepsie
WO2013174767A1 (fr) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
US9486411B2 (en) 2012-06-05 2016-11-08 Takeda Pharmaceutical Company Limited Solid preparation
WO2014013505A2 (fr) * 2012-07-20 2014-01-23 Hetero Research Foundation Vildagliptine amorphe
EP2769712A1 (fr) * 2013-02-21 2014-08-27 Siegfried International AG Formulation pharmaceutique comportant des agglomérats d'inhibiteur DPP-IV et des particules d'inhibiteur DPP-IV
HK1213818A1 (zh) 2013-04-05 2016-07-15 勃林格殷格翰国际有限公司 依帕列净的治疗用途
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
ES2702174T3 (es) 2013-04-05 2019-02-27 Boehringer Ingelheim Int Usos terapéuticos de empagliflozina
CA2812519A1 (fr) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Composition pharmaceutique, procedes pour le traitement et utilisations de celle-ci
DK2986304T3 (da) 2013-04-18 2022-04-04 Boehringer Ingelheim Int Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf.
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
TR201402685A1 (tr) 2014-03-06 2015-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vildagliptinin farmasotik formulasyonları.
US20170014380A1 (en) 2014-03-06 2017-01-19 Sanovell IIac Sanayi Ve Ticaret Anonim Sirketi Vildagliptin Formulation Process Under Inert Gas Atmosphere
US10342247B2 (en) 2014-07-21 2019-07-09 Roquette Freres Sugar compositions for tableting by direct compression
CN107072781B (zh) * 2014-09-11 2019-02-01 阿普力特医疗股份有限公司 用于治疗声门闭合不全的方法和设备
CN104817482B (zh) * 2015-03-17 2017-05-10 宁波百思佳医药科技有限公司 2‑取代吡咯烷类化合物、制备方法及其在制备维格列汀中的应用
MX390363B (es) 2016-06-10 2025-03-20 Boehringer Ingelheim Int Combinacion de linagliptina y metformina
WO2018050892A1 (fr) 2016-09-16 2018-03-22 Galenicum Health S.L. Compositions pharmaceutiques de vildagliptine
CN109922813A (zh) 2016-11-10 2019-06-21 勃林格殷格翰国际有限公司 药物组合物、治疗方法及其用途
US11730585B2 (en) 2016-11-15 2023-08-22 Ramot At Tel-Aviv University Ltd. Tissue repair device and method
GR1009406B (el) 2017-10-03 2018-11-26 Φαρματεν Αβεε Φαρμακευτικο σκευασμα που περιλαμβανει βιλνταγλιπτινη και μεθοδος για την παρασκευη αυτου
KR102622198B1 (ko) * 2018-03-30 2024-01-09 한미약품 주식회사 빌다글립틴을 함유하는 경구용 고형제제 및 그의 제조 방법
WO2019217800A1 (fr) * 2018-05-10 2019-11-14 La'au Pono Réduction en poudre d'extrait de cannabis à usage médical par l'intermédiaire d'une procédure de granulation par voie humide
EP3793529A1 (fr) * 2018-05-18 2021-03-24 Galenicum Health S.L.U. Compositions pharmaceutiques stables d'inhibiteurs de dpp-iv en combinaison avec de la metformine sous la forme de comprimés à libération immédiate
GR1009644B (el) 2018-09-25 2019-11-12 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει βιλνταγλιπτινη και μετφορμινη και μεθοδος για την παρασκευη αυτου
WO2021076066A1 (fr) 2019-10-14 2021-04-22 Santa Farma İlaç Sanayi̇ A.Ş. Formulations orales comprenant du monohydrate de hci de sitagliptine présentant des caractéristiques pharmaceutiques améliorées
KR102362342B1 (ko) * 2020-01-31 2022-02-14 주식회사 경보제약 빌다글립틴 및 메트포민 포함하는 복합 정제
WO2022003405A1 (fr) 2020-07-03 2022-01-06 Savoi Guilherme Procédé monotope permettant d'obtenir un composé intermédiaire pyrrolidine-2-carbonitrile et procédé télescopique à l'échelle industrielle permettant de préparer du (2s)-1-[n-(3-hydroxyadamantan-1-yl)glycyl]-2-pyrrolidinecarbonitrile (vildagliptine) l'utilisant
TR202010700A2 (tr) * 2020-07-06 2022-01-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vi̇ldagli̇pti̇n ve en az bi̇r farmasöti̇k olarak kabul edi̇lebi̇li̇r eksi̇pi̇yan i̇çeren bi̇r formülasyon
CN114181129B (zh) * 2021-11-09 2024-02-13 浙江国邦药业有限公司 一种制备不同粒度维格列汀的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618845A (en) * 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
CO5150173A1 (es) * 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6248359B1 (en) * 2000-01-05 2001-06-19 Laboratorios Phoenix U.S.A., Inc. Multi-tablet oxybutynin system for treating incontinence
GB0010188D0 (en) * 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
AU2003230719A1 (en) * 2002-03-21 2003-10-08 Teva Pharmaceutical Industries Ltd. Fine particle size pioglitazone
EP1537880A4 (fr) * 2002-09-11 2009-07-01 Takeda Pharmaceutical Preparation a liberation prolongee
US7109192B2 (en) * 2002-12-03 2006-09-19 Boehringer Ingelheim Pharma Gmbh & Co Kg Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
UY28103A1 (es) * 2002-12-03 2004-06-30 Boehringer Ingelheim Pharma Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos
WO2004082665A1 (fr) * 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited Composition à libération contrôlée
PE20050021A1 (es) 2003-04-16 2005-03-15 Novartis Ag Procedimiento para la preparacion de 2-cianopirrolidina n-sustituida
BR122018014389B1 (pt) * 2004-01-20 2023-04-25 Novartis Ag Processo para preparar comprimido farmacêutico por compressão direta
KR20060124712A (ko) * 2004-02-20 2006-12-05 노파르티스 아게 신경퇴행 및 인지 장애를 치료하기 위한 ｄｐｐ ⅳ 억제제

Also Published As

Publication number Publication date
US20060210627A1 (en) 2006-09-21
RU2007131503A (ru) 2009-05-10
US20080299190A1 (en) 2008-12-04
US20120015029A1 (en) 2012-01-19
TNSN07274A1 (en) 2008-12-31
MX2007008679A (es) 2007-07-25
TW200637616A (en) 2006-11-01
AR052878A1 (es) 2007-04-11
BRPI0606731A2 (pt) 2009-07-14
AU2006206670A1 (en) 2006-07-27
CA2593359A1 (fr) 2006-07-27
WO2006078593A2 (fr) 2006-07-27
NO20074048L (no) 2007-10-11
GT200600008A (es) 2006-08-09
KR20070100291A (ko) 2007-10-10
EP1841413A2 (fr) 2007-10-10
AU2010201312A1 (en) 2010-04-22
JP2008527004A (ja) 2008-07-24
AU2006206670B2 (en) 2010-04-15
WO2006078593A3 (fr) 2006-09-14
PE20061017A1 (es) 2006-10-31
NZ555576A (en) 2010-12-24
IL183762A0 (en) 2008-04-13

Similar Documents

Publication Publication Date Title
MA29171B1 (fr) Formulation a compression directe et procede associe
TW200607801A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
TW200612949A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA04004464A (es) Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
WO2007052289A3 (fr) Nouvelle composition de comprime dispersible
TW200738280A (en) Novel pharmaceutical compositions comprising levetiracetam and process for their preparation
MA31797B1 (fr) Compositions pharmaceutiques
MA29909B1 (fr) Derives de pyridazine
TW200736258A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA05014082A (es) Acidos biariloximetilarenocarboxilicos.
TW200514772A (en) Novel tetrahydropyridine derivatives
MA27702A1 (fr) Preparation de suspensions aqueuses steriles comprenant des ingredients actifs cristallins micronises, destinees a l'inhalation
UY27548A1 (es) Sales de ácido succínico de 5,7,14-triazatetraciclo (10.3.1.02.11.04,9) exadeca-2 (11),3,5,7,9-pentaeno y composiciones farmacéuticas
TNSN07013A1 (en) Anti-histaminic composition
IL179718A0 (en) Pharmaceutical composition containing irbesartan
MA29278B1 (fr) Composition pharmaceutique comprenant un derive de l'indolylmaleimide
WO2005058890A3 (fr) Derives d'hydronopol utilises comme agonistes des recepteurs orl1 humains
TNSN04024A1 (en) Novel crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation
CA2490335A1 (fr) Composition pharmaceutique de forme solide, et methode de fabrication connexe
YU64001A (sh) Jedinjenja betahistina sa kontrolisanim oslobadjanjem
EP1831239B8 (fr) Procédé de synthèse de la gamma-lactone de l'acide 17-hydroxy-6 beta, 7 beta, 15 beta, 16 beta -bisméthylène -17 alpha- pregn-4- ène-3-one-21 carboxylique et intermédiaries-clés de ce procédé
AU2003208599A1 (en) Fosinopril formulation
TW200734333A (en) Pure and stable tiotropium bromide
TW200727892A (en) Formulations of suberoylanilide hydroxamic acid and methods for producing same
TW200640860A (en) Lercanidipine free base